All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

A phase I pharmacokinetic study of bexarotene with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer (NSCLC)

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11120%2F12%3A43905285" target="_blank" >RIV/00216208:11120/12:43905285 - isvavai.cz</a>

  • Alternative codes found

    RIV/00064211:_____/12:#0000125

  • Result on the web

    <a href="http://dx.doi.org/10.1007/s00280-011-1771-0" target="_blank" >http://dx.doi.org/10.1007/s00280-011-1771-0</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1007/s00280-011-1771-0" target="_blank" >10.1007/s00280-011-1771-0</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    A phase I pharmacokinetic study of bexarotene with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer (NSCLC)

  • Original language description

    This is a phase I study of the retinoid X receptor agonist bexarotene (Targretin) in combination with the chemotherapeutic drugs cisplatin and vinorelbine and lipid-lowering therapy. This study looked for pharmacokinetic (PK) interactions between the agents in parallel with a phase III study of the combination. Methods: Patients (n = 26) with advanced-stage non-small-cell lung cancer received intravenous cisplatin 100 mg/m2 on day 1 and at 4-week intervals plus intravenous vinorelbine 25 mg/m2 weekly. Continuous oral bexarotene therapy (400 mg/m2/day) was initiated at day 4. Lipid-lowering therapy was initiated in all patients due to hypertriglyceridemia associated with bexarotene use. PK profiles of the chemotherapeutic agents were obtained on day 1 (without bexarotene) and during cycles 2-4 (with bexarotene). Vinorelbine (n = 18) and free cisplatin (n = 17) PK parameters in evaluable patients were determined using non-compartmental methods. Results: Mean vinorelbine and free cisplati

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

  • CEP classification

    FC - Pneumology

  • OECD FORD branch

Result continuities

  • Project

  • Continuities

    N - Vyzkumna aktivita podporovana z neverejnych zdroju

Others

  • Publication year

    2012

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    Cancer Chemotherapy and Pharmacology

  • ISSN

    0344-5704

  • e-ISSN

  • Volume of the periodical

    69

  • Issue of the periodical within the volume

    3

  • Country of publishing house

    US - UNITED STATES

  • Number of pages

    10

  • Pages from-to

    815-824

  • UT code for WoS article

    000302325600025

  • EID of the result in the Scopus database